Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Damanhour Teaching Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Egypt register with Damanhour Teaching Hospital as lead sponsor. Synced 12 Nov 2026
5Current trials
5Recruiting now
4Drugs in these trials
1Trial register
At a glance

Damanhour Teaching Hospital is the lead sponsor of 5 current clinical trials in our Egypt register. 5 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Dexamethasone, Dexamethasone phosphate and Dexmedetomidine. The most-studied condition is Post Operative Pain.

ClinicalTrials.gov trials by status

  • Recruiting5100%

Trials by phase

  • Not applicable360%
  • Phase 4240%
01

Clinical trials sponsored by Damanhour Teaching Hospital

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block
NCT05793060 · ClinicalTrials.gov ↗ · Analgesia
Phase 4 Recruiting 2026-08 Egypt
Rhomboid Intercostal Block Versus Retrolaminar Block for Postoperative Analgesia After Thoracoscopic Sympathectomy
NCT06653803 · ClinicalTrials.gov ↗ · Post Operative Pain
Not applicable Recruiting 2026-08 Egypt
Nylon Versus Polyurethane Epidural Catheters In Patients Undergoing Major Orthopedic Surgery
NCT05168943 · ClinicalTrials.gov ↗ · Epidural; Anesthesia, Catheter Complications, Catheter Blockage
Not applicable Recruiting 2026-07 Egypt
Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries
NCT04914234 · ClinicalTrials.gov ↗ · Hypotension Drug-Induced
Phase 4 Recruiting 2025-12 Egypt
Erector Spinae Plane Block Versus Rectus Sheath Block for Postoperative Analgesia After Supraumbilical Surgery
NCT05179928 · ClinicalTrials.gov ↗ · Post Operative Pain
Not applicable Recruiting 2026-08 Egypt

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Damanhour Teaching Hospital trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Damanhour Teaching Hospital trials

7 conditions
Post Operative Pain2Analgesia1Epidural; Anesthesia1Catheter Complications1Catheter Blockage1Catheter Dysfunction1Hypotension Drug-Induced1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Egypt55

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Post Operative Pain

SponsorTrials
Ain Shams University6
Minia University4
Kasr El Aini Hospital2

Sponsors with the most current trials registered for this condition.

06

Questions about Damanhour Teaching Hospital trials

How many clinical trials does Damanhour Teaching Hospital sponsor?

Damanhour Teaching Hospital is the lead sponsor of 5 current trials on ClinicalTrials.gov in our Egypt register, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Damanhour Teaching Hospital trials recruiting?

Yes. 5 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Damanhour Teaching Hospital testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Dexamethasone (1), Dexamethasone phosphate (1), Dexmedetomidine (1) and Metoprolol Succinate (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.